Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum

Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were evaluated in 14 patients who were admitted to the hospital due to an acute episode of schizophrenia or schizoaffective disorder. The collected data included demographic characteristics, history of disorder and previous treatment, and details of cariprazine therapy such as dosing, side effects and measurements of effectiveness via scales. Difference between admission and discharge on the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression-Severity (CGI-S) scale scores were evaluated using the Wilcoxon Signed-Rank test. Significant improvement was detected in nearly all patients (one patient dropped out) as measured by the BPRS Total, Negative symptom, Positive symptom, and Hostility scores. At admission, patients were markedly-moderately ill and at discharge the severity was reduced to borderline ill and normal according to the CGI-S. The CGI-Improvement scale also indicated very much and much improvement at discharge. Importantly, patients left the hospital with high doses of cariprazine, i.e., 7.5 mg/day or even 9.0 mg/day, but this did not cause safety problems; cariprazine well-tolerated as only a few patients experienced side effects such as akathisia. The results provide novel evidence regarding the tolerability and effectiveness of cariprazine in high doses patients on the schizophrenia spectrum

Adverse effect · Akathisia · Antipsychotic · Brief Psychiatric Rating Scale · Clinical Global Impression · Global Assessment of Functioning · Placebo · Psychiatry · Psychosis · Rating scale · Schizoaffective disorder · Schizophrenia (object-oriented programming · Tolerability · Bipolar Disorder and Treatment · Electroconvulsive Therapy Studies · Medicine · Psychology · Schizophrenia research and treatment · Internal Medicine

• A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia

  Open Access•Claudia Carmassi, Valerio Dell’Oste et al.•Frontiers in Psychiatry•2024

  Add to list

• Dosing Cariprazine Within and Beyond Clinical Trials

  Open Access•Elmārs Rancāns, Z B Dombi et al.•Frontiers in Psychiatry•2022

  Add to list

• The Brief Psychiatric Rating Scale

  Open Access•John E Overall, Donald R Gorham•Psychological Reports•1962

  Add to list